Qingkailing Injection Versus Puerarin Injection on Withdrawal Rate of Corticosteroids in Patients With Active Rheumatoid Arthritis

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of Qingkailing injection versus Puerarin injection on withdrawal rate of corticosteroids in patients with active rheumatoid arthritis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chengdu PLA General Hospital
• Treatments: Puerarin

Criteria

Inclusion Criteria:

• with active RA

• without taking any other medication for the treatment of active RA in at least 4 last weeks

• aged from 18 to 75 years

• without conflict to the written, informed consent signed prior to the enrollment.

Exclusion Criteria:

• being included in other clinical trial within the last 4 weeks

• with abnormal liver or kidney function (more than 1 time above the high normal)

• with serious cardiovascular disease

• with hematologic disease

• being in pregnancy, lactation period or under a pregnancy plan

• with severe gastrointestinal disease

• with contraindication or being allergic to the test drugs

• being under the treatment of drugs within 1 previous week, that might affect the results of the trial, such as non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, immunosuppressants, anti-ulcer drugs

• being not compatible for the trial medication, or other circumstances at the discretion of investigators

• without legal capacity or only with limited legal capacity.